


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

Use this form for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

10/568,194

Filing Date

February 10, 2006

First Named Inventor

Veronica Bordoni

Art Unit

1645

Examiner Name

Unknown

Attorney Docket Number

NOTAR-033US

## ENCLOSURES (Check all that apply)

☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Certified Copy of Priority Document(s)

☐Reply to Missing Parts/  
Incomplete Application☐Reply to Missing Parts  
under 37 CFR 1.52 or 1.53☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐Petition to Convert to a  
Provisional Application☐

Power of Attorney, Revocation

☐

Change of Correspondence Address

☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) \_\_\_\_\_

☐ Landscape Table on CD☐

After Allowance Communication to TC

☐Appeal Communication to Board  
of Appeals and Interferences☐Appeal Communication to TC  
(Appeal Notice, Brief, Reply Brief)☐

Proprietary Information

☐

Status Letter

☒Other Enclosure(s) (please identify  
below):Certificate of Mailing; Return Receipt  
Postcard

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Stetina Branda Garred &amp; Brucker

Signature

Printed name

Kit M. Stetina

Date

December 11, 2006

Reg. No.

29,445

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Josephine I. Weissberger


Date

December 11, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Case NOTAR-033US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **Veronica Bordoni** )  
**Tonino Alonzi** )  
**Marco Tripodi** )  
Serial No.: **10/568,194** ) Art Unit: **1645**  
Filing Date: **February 10, 2006** ) Examiner: **Unknown**  
For: **CONDITIONED CELL** )  
**CULTURE MEDIUM, METHOD** )  
**TO OBTAIN THE SAME AND** )  
**USE OF IT FOR MAINTENANCE,** )  
**PROLIFERATION AND** )  
**DIFFERENTIATION OF** )  
**MAMMALIAN CELLS** )

---

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. SECTION 1.97**

Mail Stop Amendment  
Assistant Commissioner for Patents  
Post Office Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir/Madam:

Pursuant to 37 C.F.R. § 1.97, the following Supplemental Information Disclosure Statement is submitted as listed on form PTO/SB/08B enclosed herewith in duplicate. Copies of all disclosure documents are attached hereto for the Examiner's review.

No representation is made that the references disclosed herein legally constitute prior art, or that more relevant references are not available. The disclosure documents enclosed herewith and listed on the attached form PTO/SB/08B are printed in the English language and/or accompanied by an Abstract published in the English language.

The references listed herein, when taken alone or in combination, are not believed to disclose nor make obvious the invention as claimed in the subject application.

As this Supplemental Information Disclosure Statement is being submitted before the stipulated three months from the filing date of the application and/or before the mailing of a first Office Action, it is believed that no fee is required.


If a fee is required, please charge Account Number 19-4330.


Respectfully submitted,

Dated: December 11, 2006

Customer No. 007663

By:

  
\_\_\_\_\_  
Kit M. Stetina, Esq.  
Registration No. 29,445  
STETINA BRUNDA GARRED & BRUCKER  
75 Enterprise, Suite 250  
Aliso Viejo, CA 92656  
(949) 855-1246



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

### Complete if Known

Application Number	10/568,194
Filing Date	February 10, 2006
First Named Inventor	Veronica Bordonì
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	NOTAR-033US

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ELLEN KITTLER, ET AL; "Biologic Significance of Constitutive and Subliminal Growth Factor Production by Bone Marrow Stroma"; Blood; 06/15/1992; pgs 3168-3178; Vol. 79, No. 12	
		CONNIE EVANS ET AL.; "Mechanisms That Regulate the Cell Cycle Status of Very Primitive Hematopoietic Cells In Long-Term Human Marrow Cultures. II. Analysis of Positive and Negative Regulators Produced by Stromal Cells Within the Adherent Layer"; Blood; 07/01/1991; pgs. 110-117; Vol. 78, No. 1	
		P.H. KREBSBACH ET AL; "Bone Marrow Stromal Cells: Characterization and Clinical Application"; Crit. Rev. Oral Biol Med.; 1999; pgs. 165-181	
		PIERRE CHARBORD ET AL.; "Comparative Study of Stromal Cell Lines Derived from Embryonic, Fetal, and PostNatal Mouse Blood-Forming Tissues"; www.sciencedirect.com; 11/13/2006; 2 pgs.	
		FRANCESCA SPAGNOLI ET AL.; "Identification of Bipotential Precursor Cell in Hepatic Cell Lines Derived from Transgenic Mice Expressing Syto-Met in the Liver"; The Journal of Cell Biology; 11/16/1998; pgs. 1101-1112; Vol. 143, No. 4	
		D BELLOVINO ET AL.; "MMH Cells: An in Vitro Model for the Study of Retinol-Binding Protein Secretion Regulated by Retinol"; www.interscience.wiley.com; 11/13/2006; 3 pgs.	
		FRANCESCA SPAGNOLI ET AL.; "Inhibition of MMH (Met Murine Hepatocyte) Cell Differentiation by TGF is Abrogated by Pre-Treatment with Heritable Differentiation Effector FGF1"; Journal of Cell Science; 2000; pgs. 3639-3647	
		M. NAPOLITANO ET AL; "Oxidation Affects the Regulation of Hepatic Lipid Synthesis by Chylomicron Remnants"; www.ncbi.nlm.nih.gov; 11/13/2006; 1 pg.	
		VALERIE PASQUETTO ET AL.; "Cytokine-Sensitive Replication of Hepatitis B Virus in Immortalized Mouse Hepatocyte Cultures"; Journal of Virology; 06/2000; pgs. 5646-5653; Vol. 76, No. 11	
		DAVID PENINGTON; "Megakaryocyte Colony Culture Using a Liver Cell Conditioned Medium"; Blood Cells; 1979; pgs. 13-23;	
		FRANZISKA BOESS ET AL.; "Gene Expression in Two Hepatic Cell Lines, Cultured Primary Hepatocytes, and Liver Slices Compared to the In Vitro Liver Gene Expression in Rats: Possible Implications for Toxicogenomics Use of in In Vitro Systems"; Toxicological Sciences; 2003; pgs. 386-402	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **1** of **2**

## Complete if Known

Application Number	10/568.194
Filing Date	February 10, 2006
First Named Inventor	Veronica Bordon
Group Art Unit	1645
Examiner Name	Unknown
Attorney Docket Number	NOTAR-033US

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		JOAN MASSAGUE ET AL.; "Stimulation by Insulin-Like Growth Factors is Required for Cellular Transformation by Type Transforming Growth Factor"; The Journal of Biological Chem.; 04/25/1985; pgs.	
		HIDEJI NAKAMURA ET AL.; "Molecular Cloning of Complementary DNA for a Novel Human Hepatoma-Derived Growth Factor"; The Journal of Biological Chemistry; 10/07/1994; pgs. 25143-25149; Vol. 269; No. 40	
		KATRINA ALLEN ET AL.; "Conditionally Immortalized Mouse Hepatocytes for Use in Liver Gene Therapy"; www.blackwell-synergy.com; 11/13/2006; 2 pgs.	
		G. BARBANTI-BRODANO ET AL.; "Simian Virus 40 Infection in Humans and Association with Human Diseases: Results and Hypotheses; www.ncbi.nlm.nih.com; 11/13/2006; 2 pgs.	
		P. KRAUSE ET AL.; "Hepatocyte-Supported Serum-Free Culture of Rat Liver Sinusoidal Endothelial Cells"; www.ncbi.nlm.nih.com; 11/06/2006; 1 pg.	
		WOLFRAM HAUPT ET AL.; "Post-Transcriptional Inhibition of Glutamine Synthetase Induction in Rat Liver Epithelial Cells Exerted by Conditioned Medium from Rat Hepatocytes; Life Sciences; 2000; pgs. 3191-3198;	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.